Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial Read More » September 26, 2023
Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure Read More » September 26, 2023
PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial Read More » September 22, 2023
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH Read More » September 15, 2023
Medmain Inc. Has Been Selected for the U.S. Market Gateway Accelerator for BioSciences and MedTech Read More » September 12, 2023